Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Keratoconus

In brief

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Key facts

Study ID

NCT07400952

Run by

Glaukos Corporation

People needed

100

Starts

2025-12-23

Expected to finish

2027-04-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be ≥ 18 and ≤ 55 years of age
• Diagnosis of keratoconus in the study eye

You may not qualify if…

• Pregnant, lactating or planning a pregnancy
• Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Where it is running

• Glaukos Clinical Study Site — Westerville, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.